Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/asthma-versus-chronic-obstructive-pulmonary-disease-the-dutch-versus-Q1FhDXzDfX
References (68)
-
J. Wedzicha, D. Banerji, K. Chapman, J. Vestbo, N. Roche, R. Ayers, C. Thach, R. Fogel, F. Patalano, C. Vogelmeier (2016)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.The New England journal of medicine, 374 23
-
I. Pavord, S. Lettis, N. Locantore, S. Pascoe, P. Jones, J. Wedzicha, N. Barnes (2015)
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax, 71
-
Sanghun Choi, E. Hoffman, S. Wenzel, M. Castro, S. Fain, N. Jarjour, M. Schiebler, Kun Chen, Ching-Long Lin (2017)
Quantitative computed tomographic imaging–based clustering differentiates asthmatic subgroups with distinctive clinical phenotypesThe Journal of Allergy and Clinical Immunology, 140
-
Hector Ortega, Mark Liu, I. Pavord, Guy Brusselle, J. FitzGerald, A. Chetta, M. Humbert, Lynn Katz, O. Keene, Steve Yancey, P. Chanez (2014)
Mepolizumab treatment in patients with severe eosinophilic asthma.The New England journal of medicine, 371 13
-
P. Barnes (2000)
Mechanisms in COPD: differences from asthma.Chest, 117 2 Suppl
-
Xavier Soler, J. Ramsdell (2015)
Are Asthma and COPD a Continuum of the Same Disease?The journal of allergy and clinical immunology. In practice, 3 4
-
N. Anthonisen (2004)
The British hypothesis revisitedEuropean Respiratory Journal, 23
-
L. George, C. Brightling (2016)
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary diseaseTherapeutic Advances in Chronic Disease, 7
-
I. Pavord, P. Chanez, G. Criner, H. Kerstjens, S. Korn, N. Lugogo, J. Martinot, H. Sagara, F. Albers, E. Bradford, S. Harris, B. Mayer, D. Rubin, S. Yancey, F. Sciurba (2017)
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 377
-
M. Ghebre, M. Bafadhel, D. Desai, Suzanne Cohen, P. Newbold, L. Rapley, J. Woods, P. Rugman, I. Pavord, C. Newby, P. Burton, R. May, C. Brightling (2015)
Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary diseaseThe Journal of Allergy and Clinical Immunology, 135
-
E. Bel, A. Brinke (2017)
New Anti‐Eosinophil Drugs for Asthma and COPD: Targeting the Trait!Chest, 152
-
E. Bleecker, J. FitzGerald, P. Chanez, A. Papi, S. Weinstein, P. Barker, Stephanie Sproule, G. Gilmartin, M. Aurivillius, V. Werkström, M. Goldman (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 388
-
H. Reddel, E. Bateman, A. Becker, L. Boulet, Á. Cruz, J. Drazen, T. Haahtela, S. Hurd, H. Inoue, J. Jongste, R. Lemanske, M. Levy, P. O'Byrne, P. Paggiaro, S. Pedersen, E. Pizzichini, Manuel Soto‐Quiroz, S. Szefler, G. Wong, J. FitzGerald (2015)
A summary of the new GINA strategy: a roadmap to asthma controlThe European Respiratory Journal, 46
-
W. Moore, E. Bleecker, D. Curran-Everett, S. Erzurum, B. Ameredes, L. Bacharier, W. Calhoun, M. Castro, K. Chung, Melissa Clark, R. Dweik, A. Fitzpatrick, B. Gaston, M. Hew, I. Hussain, N. Jarjour, E. Israel, B. Levy, James Murphy, S. Peters, W. Teague, D. Meyers, W. Busse, S. Wenzel (2007)
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.The Journal of allergy and clinical immunology, 119 2
-
A. Pepper, H. Renz, T. Casale, H. Garn (2017)
Biologic Therapy and Novel Molecular Targets of Severe Asthma.The journal of allergy and clinical immunology. In practice, 5 4
-
Blanchard (2009)
Biology of the eosinophilAdv Immunol, 101
-
J. Vestbo, S. Hurd, A. Agustí, P. Jones, Claus Vogelmeier, A. Anzueto, P. Barnes, L. Fabbri, F. Martinez, M. Nishimura, R. Stockley, D. Sin, R. Rodríguez-Roisín (2007)
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.American journal of respiratory and critical care medicine, 187 4
-
P. Barnes (2016)
Asthma-COPD Overlap.Chest, 149 1
-
C. Brightling, E. Bleecker, R. Panettieri, M. Bafadhel, D. She, C. Ward, Xiao Xu, Claire Birrell, R. Merwe (2014)
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.The Lancet. Respiratory medicine, 2 11
-
J. Ivanova, R. Bergman, H. Birnbaum, G. Colice, R. Silverman, K. McLaurin (2012)
Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.The Journal of allergy and clinical immunology, 129 5
-
The host factor in bronchitis -
P. Collins, S. Marleau, D. Griffiths-Johnson, P. Jose, T. Williams (1995)
Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivoThe Journal of Experimental Medicine, 182
-
D. Postma, K. Rabe (2015)
The Asthma-COPD Overlap Syndrome.The New England journal of medicine, 373 13
-
M. Giannetti, J. Cardet (2016)
Interleukin-5 Antagonists Usher in a New Generation of Asthma TherapyCurrent Allergy and Asthma Reports, 16
-
N. Gross, P. Barnes (2017)
New Therapies for Asthma and Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 195
-
R. Tkacova, Darlene Dai, J. Vonk, J. Leung, P. Hiemstra, M. Berge, L. Kunz, Z. Hollander, D. Tashkin, R. Wise, J. Connett, R. Ng, B. McManus, S. Man, D. Postma, D. Sin (2016)
Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?The Journal of allergy and clinical immunology, 138 6
-
P. Hekking, R. Wener, M. Amelink, A. Zwinderman, M. Bouvy, E. Bel (2015)
The prevalence of severe refractory asthma.The Journal of allergy and clinical immunology, 135 4
-
(2012)
Trends in asthma prevalence, healthcare use, and mortality in the United States, 2001-2010 -
J. Fitzgerald, E. Bleecker, Parameswaran Nair, S. Korn, Ken Ohta, M. Lommatzsch, G. Ferguson, W. Busse, P. Barker, Stephanie Sproule, G. Gilmartin, V. Werkström, M. Aurivillius, M. Goldman (2016)
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 388
-
J. McCracken, J. Tripple, W. Calhoun (2016)
Biologic therapy in the management of asthmaCurrent Opinion in Allergy and Clinical Immunology, 16
-
F. Speizer, J. Ware (2015)
Exploring Different Phenotypes of COPD.The New England journal of medicine, 373 2
-
M. Kraft (2006)
Asthma and chronic obstructive pulmonary disease exhibit common origins in any country!American journal of respiratory and critical care medicine, 174 3
-
S. Barnett, T. Nurmagambetov (2011)
Costs of asthma in the United States: 2002-2007.The Journal of allergy and clinical immunology, 127 1
-
A. Muraro, R. Lemanske, P. Hellings, C. Akdis, T. Bieber, T. Casale, M. Jutel, P. Ong, L. Poulsen, P. Schmid‐Grendelmeier, H. Simon, S. Seys, I. Agache (2016)
Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.The Journal of allergy and clinical immunology, 137 5
-
K. Takatsu, H. Nakajima (2008)
IL-5 and eosinophilia.Current opinion in immunology, 20 3
-
M. McGeachie, Katherine Yates, Xiaobo Zhou, F. Guo, A. Sternberg, M. Natta, R. Wise, S. Szefler, Sunita Sharma, A. Kho, M. Cho, Damien Croteau-Chonka, P. Castaldi, Gaurav Jain, Amartya Sanyal, Amartya Sanyal, Y. Zhan, B. Lajoie, B. Lajoie, J. Dekker, J. Stamatoyannopoulos, R. Covar, R. Covar, R. Zeiger, R. Zeiger, N. Adkinson, Paul Williams, H. Kelly, H. Grasemann, J. Vonk, G. Koppelman, D. Postma, B. Raby, I. Houston, Q. Lu, A. Fuhlbrigge, K. Tantisira, E. Silverman, James Tonascia, S. Weiss, R. Strunk (2016)
Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma.The New England journal of medicine, 374 19
-
P. Barnes (2008)
Immunology of asthma and chronic obstructive pulmonary diseaseNature Reviews Immunology, 8
-
W. Moore, D. Meyers, S. Wenzel, W. Teague, Huashi Li, Xingnan Li, R. D'Agostino, M. Castro, D. Curran-Everett, Anne Fitzpatrick, B. Gaston, N. Jarjour, R. Sorkness, William Calhoun, K. Chung, S. Comhair, R. Dweik, E. Israel, Stephen Peters, William Busse, S. Erzurum, E. Bleecker (2010)
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.American journal of respiratory and critical care medicine, 181 4
-
Parameswaran Nair, M. Pizzichini, M. Kjarsgaard, M. Inman, A. Efthimiadis, E. Pizzichini, F. Hargreave, P. O'Byrne (2009)
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.The New England journal of medicine, 360 10
-
C. Lombardi, E. Raffetti, M. Caminati, G. Liccardi, G. Passalacqua, F. Reccardini, E. Ridolo, G. Senna, G. Steinhilber, M. Milanese (2016)
Phenotyping asthma in the elderly: allergic sensitization profile and upper airways comorbidity in patients older than 65 years.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 116 3
-
Fletcher (1959)
Chronic bronchitis. Its prevalence, nature, and pathogenesisAm Rev Respir Dis, 80
-
김미경 (1997)
Biology of eosinophil, 1997
-
P. Barnes (2006)
Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases.American journal of respiratory and critical care medicine, 174 3
-
National Asthma Education Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007
J Allergy Clin Immunol, 120
-
M. Castro, S. Mathur, F. Hargreave, L. Boulet, F. Xie, James Young, H. Wilkins, T. Henkel, Parameswaran Nair (2011)
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.American journal of respiratory and critical care medicine, 184 10
-
P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, L. Brannick, D. Robinson, S. Wenzel, W. Busse, T. Hansel, N. Barnes (2007)
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.American journal of respiratory and critical care medicine, 176 11
-
A. Fitzpatrick, W. Moore (2017)
Severe Asthma Phenotypes - How Should They Guide Evaluation and Treatment?The journal of allergy and clinical immunology. In practice, 5 4
-
Claus Vogelmeier, Gerard Criner, Fernando Martinez, A. Anzueto, Peter Barnes, J. Bourbeau, B. Celli, Rongchang Chen, Marc Decramer, Leonardo Fabbri, P. Frith, David M.G. Halpin, M. Varela, M. Nishimura, N. Roche, R. Rodríguez-Roisín, Don Sin, D. Singh, R. Stockley, J. Vestbo, J. Wedzicha, A. Agustí (2017)
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.American journal of respiratory and critical care medicine, 195 5
-
K. Chung, S. Wenzel, J. Brożek, A. Bush, M. Castro, P. Sterk, I. Adcock, E. Bateman, E. Bel, E. Bleecker, L. Boulet, C. Brightling, P. Chanez, S. Dahlén, R. Djukanović, U. Frey, M. Gaga, Peter Gibson, Q. Hamid, Nizar Jajour, T. Mauad, R. Sorkness, W. Teague (2013)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 43
-
P. Barnes (2017)
Cellular and molecular mechanisms of asthma and COPD.Clinical science, 131 13
-
D. Caillaud, P. Chanez, R. Escamilla, P. Burgel, I. Court-Fortune, P. Nesme-Meyer, G. Deslée, T. Pérez, J. Paillasseur, C. Pinet, G. Jébrak, N. Roche (2017)
Asthma–COPD overlap syndrome (ACOS) vs ‘pure’ COPD: a distinct phenotype?Allergy, 72
-
M. Leckie, A. Brinke, Jamey Khan, Z. Diamant, B. O'connor, Christine Walls, A. Mathur, Hugh Cowley, K. Chung, R. Djukanović, T. Hansel, S. Holgate, P. Sterk, P. Barnes (2000)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic responseThe Lancet, 356
-
H. Coumou, E. Bel (2016)
Improving the diagnosis of eosinophilic asthmaExpert Review of Respiratory Medicine, 10
-
I. Pavord, S. Korn, P. Howarth, E. Bleecker, R. Buhl, O. Keene, Hector Ortega, P. Chanez (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 380
-
E. Ford, L. Murphy, Olga Khavjou, W. Giles, J. Holt, J. Croft (2015)
Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.Chest, 147 1
-
D. Vercelli (2008)
Discovering susceptibility genes for asthma and allergyNature Reviews Immunology, 8
-
Parameswaran Nair, S. Wenzel, K. Rabe, A. Bourdin, N. Lugogo, P. Kuna, P. Barker, Stephanie Sproule, S. Ponnarambil, M. Goldman (2017)
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaThe New England Journal of Medicine, 376
-
R. Kolbeck, A. Kozhich, M. Koike, Li Peng, C. Andersson, M. Damschroder, J. Reed, R. Woods, W. Dall'acqua, G. Stephens, J. Erjefalt, L. Bjermer, A. Humbles, D. Gossage, Herren Wu, P. Kiener, G. Spitalny, C. Mackay, N. Molfino, A. Coyle (2010)
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.The Journal of allergy and clinical immunology, 125 6
-
N. Roche, K. Chapman, C. Vogelmeier, F. Herth, C. Thach, R. Fogel, P. Olsson, F. Patalano, D. Banerji, J. Wedzicha (2017)
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME TrialAmerican Journal of Respiratory and Critical Care Medicine, 195
-
T. Carr, M. Kraft (2017)
Management of Severe Asthma before Referral to the Severe Asthma Specialist.The journal of allergy and clinical immunology. In practice, 5 4
-
J. Tripple, J. McCracken, W. Calhoun (2017)
Biologic Therapy in Chronic Obstructive Pulmonary Disease.Immunology and allergy clinics of North America, 37 2
-
R. Zeiger, M. Schatz, Anand Dalal, Wansu Chen, E. Sadikova, R. Suruki, A. Kawatkar, L. Qian (2017)
Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study.The journal of allergy and clinical immunology. In practice, 5 1
-
S. Christenson, K. Steiling, M. Berge, Kahkeshan Hijazi, P. Hiemstra, DIRKJE S. Postma, M. Lenburg, A. Spira, P. Woodruff (2015)
Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease.American journal of respiratory and critical care medicine, 191 7
-
National Surveillance of Asthma: United States, 2001-2010 -
A. Dasgupta, M. Kjarsgaard, D. Capaldi, K. Radford, Fernando Aleman, C. Boylan, L. Altman, T. Wight, G. Parraga, P. O'Byrne, Parameswaran Nair (2017)
A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitisEuropean Respiratory Journal, 49
-
E. Bel, S. Wenzel, P. Thompson, C. Prazma, O. Keene, S. Yancey, H. Ortega, I. Pavord (2014)
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.The New England journal of medicine, 371 13
-
M. Castro, J. Zangrilli, M. Wechsler, E. Bateman, G. Brusselle, P. Bardin, K. Murphy, J. Maspero, C. O'Brien, S. Korn (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.The Lancet. Respiratory medicine, 3 5
-
P. Flood-Page, A. Menzies-Gow, A. Kay, D. Robinson (2003)
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.American journal of respiratory and critical care medicine, 167 2
- Publisher
- Wolters Kluwer Health
- Copyright
- Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
- ISSN
- 1528-4050
- eISSN
- 1473-6322
- DOI
- 10.1097/ACI.0000000000000409
- pmid
- 29257776
- Publisher site
- See Article on Publisher Site
Abstract
Purpose of reviewAsthma and COPD represent heterogeneous disorders with broad ranging impact on patients and health systems. This review focuses on evidence for early attempts at understanding their pathogenesis by the British and Dutch hypotheses. It also addresses the role of eosinophils, IL-5, and biologics targeting these pathways in asthma and COPD.Recent findingsAmong asthma and COPD patients, clusters exist based on phenotypic and biologic markers allowing for further understanding of endotypes. Recent studies suggest the role of eosinophils and optimal therapies for each condition may be different.SummaryAlthough patients with ACOS or overlap symptoms may be an exception, overall there appears to be more evidence supporting that asthma and COPD are distinct processes. Targeting eosinophils with anti-IL-5 therapy appears to be an exciting pathway in the properly selected patient with asthma and recent data also supports its use in COPD.
Journal
Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health
Published: Feb 1, 2018